This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Bharath B R
Atrimed Biotech LLp
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Human coronavirus (SARS-CoV-2) is causing a pandemic with significant morbidity and mortality. Although, no effective novel drugs are available, drug repurposing is emerging as an effective strategy. In this study, we present an in silico drug repurposing study implementing successful concepts of computer aided drug design (CADD) technology with an objective to repurpose known drugs to interfere the viral cellular entry via the spike glycoprotein (SARS-CoV-2-S), which mediates the virus–cell receptor interaction. SARS-CoV-2-S uses ACE2 to enter cells. Totally, 4015 known and approved small molecules were screened for interaction with SARS-CoV-2 S through docking studies and 15 lead molecules were shortlisted. Further, three molecules streptomycin, ciprofloxacin and Glycyrrhizic acid (GA) were selected based on their reported anti-viral activity, safety, availability, affordability and subjected for Molecular Dynamics (MD) simulation. The MD simulation results indicate that GA from plant origin may be repurposed against SARS-CoV-2 and further studies are needed for validation.
Keywords
SARS-CoV-2, Pathogen host interaction, SARS-CoV-2 Spike Glycoprotein, ACE2, Small Molecules
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 13 May, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Bharath B R
Atrimed Biotech LLp
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 13 May, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Human coronavirus (SARS-CoV-2) is causing a pandemic with significant morbidity and mortality. Although, no effective novel drugs are available, drug repurposing is emerging as an effective strategy. In this study, we present an in silico drug repurposing study implementing successful concepts of computer aided drug design (CADD) technology with an objective to repurpose known drugs to interfere the viral cellular entry via the spike glycoprotein (SARS-CoV-2-S), which mediates the virus–cell receptor interaction. SARS-CoV-2-S uses ACE2 to enter cells. Totally, 4015 known and approved small molecules were screened for interaction with SARS-CoV-2 S through docking studies and 15 lead molecules were shortlisted. Further, three molecules streptomycin, ciprofloxacin and Glycyrrhizic acid (GA) were selected based on their reported anti-viral activity, safety, availability, affordability and subjected for Molecular Dynamics (MD) simulation. The MD simulation results indicate that GA from plant origin may be repurposed against SARS-CoV-2 and further studies are needed for validation.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
This is a list of supplementary files associated with this preprint. Click to download.
Loading...